Can I live with chronic lymphocytic leukemia (CLL) given an absolute lymphocyte count of 748 cells/µL and no evidence of overt disease?

Can You Live with Chronic Lymphocytic Leukemia?

Yes, you can absolutely live with chronic lymphocytic leukemia (CLL), particularly with an absolute lymphocyte count of 748 cells/µL and no evidence of active disease—this represents early-stage disease that requires monitoring only, not treatment. 1

Watch-and-Wait is the Standard Approach for Early-Stage Disease

Your lymphocyte count of 748 cells/µL (0.748 × 10⁹/L) is actually below the typical CLL diagnostic threshold and well below treatment thresholds. The most recent ESMO guidelines (2021) are crystal clear: patients with early-stage CLL (Binet stage A and B, or Rai 0-II) without active disease should follow a watch-and-wait strategy 1. This is a Level I, Grade A recommendation—the highest quality evidence available.

Multiple clinical trials have definitively shown that early treatment with chemotherapy does not improve survival in early-stage CLL 1, 2. In fact, one study found that treated patients with early-stage disease had an increased frequency of fatal epithelial cancers compared to untreated patients 2.

What "Living With" CLL Actually Means

Monitoring Schedule

• First year: Blood counts and clinical examinations every 3 months 1
• After first year: Every 3-12 months depending on disease stability 1
• Physical examination should focus on lymph nodes, liver, and spleen size 1

You Do NOT Need Treatment Unless You Develop "Active Disease"

Treatment is only indicated when at least one of these criteria appears 1:

1. Progressive marrow failure: Hemoglobin <100 g/L or platelets <100 × 10⁹/L (though stable low platelets don't automatically require treatment)
2. Massive splenomegaly: ≥6 cm below left costal margin, or progressive/symptomatic
3. Massive lymphadenopathy: ≥10 cm in longest diameter, or progressive/symptomatic
4. Progressive lymphocytosis: 50% increase over 2 months OR lymphocyte doubling time <6 months (but this criterion alone is insufficient if your baseline count is <30 × 10⁹/L—which yours is) 1, 2
5. Autoimmune complications: Anemia or thrombocytopenia poorly responsive to corticosteroids
6. Constitutional symptoms: Unintentional weight loss ≥10% in 6 months, significant fatigue (ECOG PS ≥2), fevers >38°C for ≥2 weeks without infection, or night sweats >1 month without infection 1, 2

Critical Pitfall to Avoid

Your absolute lymphocyte count alone should NOT be used as an indicator for treatment 2. At 748 cells/µL, you're nowhere near concerning levels. Even patients with much higher counts can be safely monitored if they lack other criteria for active disease.

Long-Term Outlook

Survival and Progression

• Many patients with early-stage CLL live for years to decades without requiring treatment 1
• Research shows that even among patients with CLL-phenotype cells and lymphocytosis, CLL requiring treatment develops at only 1.1% per year 3
• Life-long observation is recommended because CLL is currently considered incurable, though some patients achieve long-lasting remissions 1

What to Watch For

• Secondary malignancies: CLL patients have a 2-7 fold increased risk of other cancers (mostly solid tumors) 1
• Richter transformation: 2-15% of patients develop transformation to aggressive lymphoma, particularly after multiple treatments 1
• Autoimmune cytopenias: Require special attention during follow-up 1

Your Specific Situation

With an absolute lymphocyte count of 748 cells/µL and no evidence of overt disease, you are in an excellent position. This count is:

• Below the traditional CLL diagnostic threshold of 5,000 cells/µL
• Far below any treatment threshold
• Consistent with either very early CLL or monoclonal B-cell lymphocytosis (MBL), which progresses to requiring treatment at only 1.1% per year 3

You should expect to live a normal lifespan with regular monitoring and no immediate need for treatment. The key is maintaining regular follow-up to detect any progression early, should it occur.